Melinda Bachini is the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 15-year survivor of ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

A survey of the nation's oncologists showed that professional burnout has reached a new high (59% vs 45% in 2013), and fewer ...

A spokesperson for the Cholangiocarcinoma Foundation writes that experimental cancer trials saved her life and could save the ...

Iovance Biotherapeutics (IOVA -0.96%), a small-cap biotech company, has an innovative approach to treating cancer that relies ...

A new way to grow T cells in the lab enables them to live longer and better destroy cancer cells in a mouse model of melanoma ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

Researchers found that radiotherapy may reduce immune cells in the tumor-immune microenvironment, potentially impacting ...

The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

Lunit offers free AI biomarker services to SITC researchers for immuno-oncology studies Global researchers gain access to ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has entered into a ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Iovance Biotherapeutics (IOVA – Research Report), ...